B+
Overall grade
A-
Financial quality
The **sleeper story** everyone's missing: Shield is already at $100M annualized run rate with 55% gross margins, tracking to become a $400M+ business by 2027 while investors fixate on oncology volumes. Yes, oncology growth accelerated to 40% (impressive after 11 years), but that's obvious. The **binding constraint** is actually sales execution, not demand: they're burning $45M per quarter on screening infrastructure with zero disclosure on rep productivity or account penetration metrics. Most revealing quote: 'We are not counting on any major [commercial] coverage before getting into ACS and USPSTF guidelines' - they've quietly walked back commercial payer expectations. My view changes if they start quantifying Shield sales metrics or if Quest partnership volume disappoints in Q1 2026.
The 30-second version
- Shield is quietly becoming the real cash machine while everyone obsesses over oncology volume
- Guardant360 Liquid's 30%+ growth after 11 years isn't market expansion, it's brutal share taking
- They're burning $45M per quarter on screening investment but won't quantify the ROI
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $232M (+31% YoY) | $265M (+39% YoY) |
| Oncology Revenue | $159M (+22% YoY) | $184M (+31% YoY) |
| Oncology Test Volume | 64K tests (+30% YoY) | 74K tests (+40% YoY) |
| Guardant360 Liquid Growth | 20%+ YoY | 30%+ YoY |
| Shield Revenue | $15M | $24M |
| Shield Tests | 16K tests | 24K tests |
| Shield Gross Margin | 48% | 55% |
| Shield ASP | $900+ | $880 |
Accountability tracked
7 new promises made4 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →